WuXi Biologics (Cayman) Inc. (2269.HK)

HKD 21.2

(0.0%)

EBITDA Summary of WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc.'s latest annual EBITDA in 2023 was 5.5 Billion CNY , down -18.02% from previous year.
WuXi Biologics (Cayman) Inc.'s latest quarterly EBITDA in 2024 Q2 was 1.23 Billion CNY , down 0.0% from previous quarter.
WuXi Biologics (Cayman) Inc. reported an annual EBITDA of 6.22 Billion CNY in 2022, up 60.41% from previous year.
WuXi Biologics (Cayman) Inc. reported an annual EBITDA of 4.51 Billion CNY in 2021, up 110.51% from previous year.
WuXi Biologics (Cayman) Inc. reported a quarterly EBITDA of 1.23 Billion CNY for 2024 Q1, up 16.21% from previous quarter.
WuXi Biologics (Cayman) Inc. reported a quarterly EBITDA of 1.33 Billion CNY for 2023 Q1, up 22.85% from previous quarter.

Annual EBITDA Chart of WuXi Biologics (Cayman) Inc. (2023 - 2014)

Historical Annual EBITDA of WuXi Biologics (Cayman) Inc. (2023 - 2014)

Year	EBITDA	EBITDA Growth
2023	5.5 Billion CNY	-18.02%
2022	6.22 Billion CNY	60.41%
2021	4.51 Billion CNY	110.51%
2020	2.31 Billion CNY	54.83%
2019	1.36 Billion CNY	30.49%
2018	881.49 Million CNY	116.42%
2017	471.39 Million CNY	45.01%
2016	319.08 Million CNY	160.18%
2015	124.93 Million CNY	33.09%
2014	93.87 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	1.23 Billion CNY	0.0%
2024 Q1	1.23 Billion CNY	16.21%
2023 Q1	1.33 Billion CNY	22.85%
2023 Q3	994.84 Million CNY	-25.25%
2023 Q2	1.33 Billion CNY	0.0%
2023 FY	- CNY	-18.02%
2023 Q4	1.06 Billion CNY	6.96%
2022 Q3	1.08 Billion CNY	-25.34%
2022 Q1	1.45 Billion CNY	70.99%
2022 FY	- CNY	60.41%
2022 Q4	1.08 Billion CNY	0.0%
2022 Q2	1.45 Billion CNY	0.0%
2021 Q2	962.54 Million CNY	0.0%
2021 Q3	848.6 Million CNY	-11.84%
2021 Q4	848.6 Million CNY	0.0%
2021 FY	- CNY	110.51%
2021 Q1	962.54 Million CNY	56.39%
2020 Q3	615.48 Million CNY	127.84%
2020 Q4	615.48 Million CNY	0.0%
2020 Q2	270.13 Million CNY	0.0%
2020 Q1	270.13 Million CNY	-12.39%
2020 FY	- CNY	54.83%
2019 Q2	262.31 Million CNY	0.0%
2019 FY	- CNY	30.49%
2019 Q4	308.34 Million CNY	0.0%
2019 Q3	308.34 Million CNY	17.55%
2019 Q1	262.31 Million CNY	49.67%
2018 FY	- CNY	116.42%
2018 Q4	175.26 Million CNY	0.0%
2018 Q3	175.26 Million CNY	11.86%
2018 Q2	156.68 Million CNY	0.0%
2018 Q1	156.68 Million CNY	7.19%
2017 Q4	146.17 Million CNY	0.0%
2017 FY	- CNY	45.01%
2017 Q2	102.9 Million CNY	0.0%
2017 Q1	102.9 Million CNY	141.05%
2017 Q3	146.17 Million CNY	42.05%
2016 Q2	75.54 Million CNY	0.0%
2016 Q4	42.69 Million CNY	0.0%
2016 FY	- CNY	160.18%
2016 Q1	75.54 Million CNY	39.88%
2015 Q3	31.23 Million CNY	0.0%
2015 Q2	31.23 Million CNY	0.0%
2015 Q1	31.23 Million CNY	0.0%
2015 FY	- CNY	33.09%
2015 Q4	54 Million CNY	72.91%
2014 Q4	31.23 Million CNY	33.09%
2014 Q1	23.46 Million CNY	0.0%
2014 Q3	23.46 Million CNY	0.0%
2014 FY	- CNY	0.0%
2014 Q2	23.46 Million CNY	0.0%
2013 Q4	23.46 Million CNY	0.0%

Peer EBITDA Comparison of WuXi Biologics (Cayman) Inc.

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	-5930.281%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	-1030.179%